SCHEMBL1198784

SCHEMBL1198784

Cc1sc(-c2cccc(C(F)(F)F)c2)cc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HDAC6 Q9UBN7 2/20 0.41
JAK2 O60674 1/20 0.41
PRF1 P14222 1/20 0.40
IL2 P60568 1/20 0.40
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADORA1 P30542 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 2/20 0.39
CES2 O00748 1/20 0.39
HPGD P15428 1/20 0.39
IKBKB O14920 1/20 0.39
BRD4 O60885 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090142 0.88 JAK2 (0.39) ALDH1A1SMN1; SMN2JAK2PRF1MAPT
SCHEMBL3102075 0.82 RAB9A (0.46) ALDH1A1SMN1; SMN2KMT2AMAPTMEN1
SCHEMBL12876562 0.81 HSD17B1 (0.40) ALDH1A1SMN1; SMN2HDAC6KMT2AMAPT
SCHEMBL13140465 0.80 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2HDAC6JAK2IL2
SCHEMBL1198680 0.77 HDAC6 (0.44) ALDH1A1SMN1; SMN2HDAC6JAK2IL2
SCHEMBL19189118 0.77 BACE1 (0.47) ALDH1A1SMN1; SMN2HDAC6JAK2IL2
SCHEMBL24951797 0.75 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HDAC6JAK2IL2
SCHEMBL29742895 0.75 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HDAC6JAK2IL2
SCHEMBL18003529 0.75 RORC (0.44) ALDH1A1SMN1; SMN2MAPTIKBKBBRD4
SCHEMBL29742821 0.74 JAK2 (0.50) ALDH1A1SMN1; SMN2HDAC6JAK2IL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102056907-B Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2014-12-31 CN disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
CN-102056907-A Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL 2011-05-11 CN disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed
WO-2009123316-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF 武田薬品工業株式会社 (JP) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885SMN1; SMN2 2057/4885HDAC6 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.